Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the publication of an international patent in relation to the Company’s NXP004 asset, which comprises novel forms of olaparib. Olaparib is currently marketed by AstraZeneca, under the Lynparza® brand name for the treatment of adults with suspected deleterious germline or somatic BRCA gene mutated ovarian, breast, or pancreatic cancer, or for suspected deleterious germline or somatic HRR gene mutated prostate cancer.
The application for the Patent, relating to new olaparib oxalic acid cocrystals, their therapeutic uses and pharmaceutical compositions containing them, was made by the Company’s wholly owned subsidiary Nuformix Technologies Limited and was filed in September 2020. The Company filed a second patent application, complementing the Patent, in November 2021 and this remains pending.
The olaparib oxalic acid cocrystals covered by the Patent may be used in the same way as olaparib. Olaparib is useful in treating diseases that benefit from PARP (Poly ADP Ribose Polymerase) inhibition. These include cancer, fibrosis, inflammatory conditions (e.g. asthma, colitis, arthritis), neurological diseases (e.g. neurodegeneration, neurotrauma, stroke), cardiovascular conditions, ophthalmic degenerative diseases, vascular diseases (e.g. diabetic complications, atherosclerosis), and various forms of critical illness (e.g. septic shock, ALI, acute liver failure). The olaparib oxalic acid cocrystals covered by the Patent may, therefore, ultimately be useful for the treatment of such diseases, disorders, and conditions.
The Company looks forward to providing further updates on progress with NXP004 and the Company’s other assets in due course.
Commenting, Alastair Riddell, Executive Chairman of Nuformix, said: “We are pleased to see the progression of the application for the Company’s first patent in relation to NXP004 to the publication stage. We believe NXP004 has significant potential and look forward to the granting of the Patent in due course. We are continuing to conduct further research and development activities on NXP004, as well as investigating future commercial opportunities. Whilst there remains much to be done, I look forward to making further announcements on our progress in the future.”
